Summary

Pharmaceutical development, epilepsy, acute care, medical countermeasures, nerve gas toxicity, status epilepticus, anti-convulsant therapy, intellectual property, orphan disease, pediatric indications, pediatric formulations, rare neurological conditions, intravenous therapeutics, oral therapeutics, suspension therapeutics

Industry

Description

Marinus is dedicated to improving treatment outcomes for patients with rare epilepsies and seizure disorders. Our lead drug candidate is designed to exhibit anti-epileptic activity by virtue of its GABAA receptor modulating properties and is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.

Special details

Specialty ethical drug manufacturing equipment

Profile

  • Incorporated in
    Delaware
  • Established since
    2003
  • Main/Branch
    Branch

Address

Contact